Neuromuscular BlockadePhase 4NCT05023343
Transmucular Quadratus Lumborum Block: Potential Quadriceps Muscle Weakness
A Phase 4 study testing Ropivacaine, Quadriceps muscle strength and Timed Up and Go in people with Neuromuscular Blockade, run by Zealand University Hospital at 1 site in Denmark.
Trial summary
The aim of this study is to examine whether the administration of the TQL block cause motor block of the lumbar plexus and thereby quadriceps muscle weakness. The investigators hypothesise that the administration of a unilateral TQL block does not cause quadriceps muscle weakness compared to a placebo block. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Neuromuscular Blockade
- What is being tested?
- Ropivacaine, Quadriceps muscle strength and Timed Up and Go
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteDenmark
- Study dates
- 2 Oct 2021to 28 Nov 2021
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- American Associations of Anaesthesiologist (ASA) class 1-2
- Have received written and oral information and signed the consent form
- Weight > 56,5 kilograms (Chosen due to maximum single dose of ropivacaine i.e. 225 milligrams)
Who cannot join
- Inability to speak and understand Danish
- Inability to cooperate
- Allergy to study drugs
- Daily intake of opioids
- Alcohol and/or drug overuse
- Fertile female participants: No use of safe contraceptives for the last month, positive urine-HCG or breastfeeding
- Previous trauma of surgery in the abdomen, hip or knee.
- Any systemic muscular or neuromuscular disease
Trial locations and contacts
1 site in 1 country.
Denmark1 site
Department of Anaesthesiology and Intensive Care Medicine, Zealand University Hospital, Roskilde
Roskilde, Region Sjælland, 4000
About this study
Official title: Does Administration of the Transmuscular Quadratus Lumborum Block Cause Quadriceps Muscle Weakness: A Randomised, Double-blinded Volunteer Study
The aim of this study is to examine whether the administration of the TQL block cause motor block of the lumbar plexus and thereby quadriceps muscle weakness. The investigators hypothesise that the administration of a unilateral TQL block does not cause quadriceps muscle weakness compared to a placebo block.
Read the detailed description
The ideal postoperative analgesic regimen following major abdominal and retroperitoneal laparoscopic surgery still lacks consensus and the discussion is ongoing. The epidural blockade has been the gold standard for postoperative pain management for major abdominal surgery for years, but with the conversion to minimal invasive surgery the procedure can rarely be justified.
The use of a multimodal analgesic regimen with opioids can cause severe side effects. These side effects can delay mobilisation after surgery, increase the risk of complications and worst of all be fatal.
The focus on an opioid sparing regimen, in the enhanced recovery setting, has been a significant motivator for the addition of ultrasound-guided nerve blocks to the perioperative progression.
At the Department of Anaesthesiology, Zealand University Hospital, the ultrasound-guided Transmuscular Quadratus Lumborum (TQL) block is part of the perioperative pain regimen for major laparoscopic abdominal and retroperitoneal surgeries, as well as for elective caesarean sections. Using the visual guidance of ultrasound, the injectate of local anaesthetic is administered in the fascial interspace between the quadratus lumborum muscle and the psoas major muscle posterior to the transversalis fascia.
This will anaesthetise the abdominal wall including both somatic and visceral nerves. No involvement of lumbar plexus i.e. the femoral nerve, obturator nerve or the lumbar part of the sympathetic trunk was observed. The lack of lumbar plexus involvement means no motor block of the lower extremities should be observed. Previous clinical studies reported no adverse events. However, the investigators did not specifically register lower limb weakness or hypotension, but on the other hand did not find any difference in ambulation or even faster ambulation compared to the placebo group.
A few case reports have reported complications related to the various quadratus lumborum blocks. Ueshima et al. reported that 90% (65/81 cases) experienced quadriceps muscle weakness following a TQL block. The incidence was 19% for posterior QL block and 1% for lateral QL block. Lower limb weakness was also reported by Wikner et al. following a bilateral lateral QL block. A case of continuous hypotension after administration of a lateral QL block has been described. One case of unilateral upper limb weakness and Horners Syndrome after a bilateral posterior QL block has also been reported. Urinary retention was reported following a continuous TQL-block. All side effects were temporary, no one reported permanent injuries. Complications have not been reported systematically.
At Zealand University Hospital, Roskilde, the investigators have administrated more than 1000 TQL blocks, and more than 300 patients have been included in various clinical trials. From clinical experience and cadaveric studies, the investigators find no evidence that the TQL block spread to the epidural space, and therefore does not cause sympathetic symptoms. Neither does the TQL block spread to the lumbar plexus, and therefore does not cause motor weakness of the lower extremities. However these notions have never been properly investigated in a controlled clinical setting, meaning that the investigators cannot entirely rule out the possibility of a spread to the lumbar plexus and thus ensuing quadriceps muscle weakness. This calls for a more in-depth investigation of this potential phenomenon.
Therefore, the aim of this study is to examine whether the administration of the TQL block cause motor block of the lumbar plexus and thereby quadriceps muscle weakness.
Prior to block administration all participants are tested using the same motor tests as after the block administration(baseline tests).
All participants will receive two TQL blocks. To keep participants and outcome assessors blinded the study drug for each side will be randomised i.e. active treatment on one side and placebo on the contralateral side.
The investigators hypothesise that the administration of a unilateral TQL block does not cause quadriceps muscle weakness compared to a placebo block.
Sub-study:
Fascial plane nerve blocks demand a great volume of local anaesthetic to achieve the right spread of local anaesthetic and thus a sufficient analgesia.
The correct concentration and volume of local anaesthetic is still debated. Studies measuring serum concentrations of local anaesthetic are rare due to time consumption and high costs. When administering a unilateral TQL block a volume of 30 ml local anaesthetic is used often equal to the maximum single-shot dose of ropivacaine; i.e. 225 milligrams. In previous studies and in the usual clinical setting the investigators have never experienced any signs of systemic toxicity, however the maximum serum concentration of local anaesthetic following TQL block administration has never been investigated. The maximum serum ropivacaine concentration following administration of a TQL block will therefore be investigated for all participants.
- Conditions
- Neuromuscular Blockade
- Being tested
- Ropivacaine, Quadriceps muscle strength, Timed Up and Go, Single-leg 6 meter timed hop test, Temperature discrimination
- Keywords
- Quadratus lumborum, Quadratus lumborum block, Ultrasound, Muscle weakness
- Medical subject headings
- Muscle Weakness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RopivacaineDrug
30 mL Ropivacaine 0,75% administered as a unilateral TQL block
Quadriceps muscle strengthOther
Quadriceps muscle strength is assessed using a hand-held dynamometer. Each participant is tested pre block administration and 60 minutes after
Timed Up and GoOther
To test mobilisation the standardised Timed Up and Go test is used. Each participant is tested pre block administration and 60 minutes after
Single-leg 6 meter timed hop testOther
To test muscle strength and power the single-leg 6 meter jump test is used. Each participant is tested pre block administration and 60 minutes after
Temperature discriminationOther
Dermatomal evaluation of cold and warm discrimination of the thoracic and lumbar dermatomes Approximately 60 minutes after block administration
Pinprick testOther
Dermatomal evaluation of pinprick/sharp sensation of the thoracic and lumbar dermatomes.
Approximately 60 minutes after block administration
Blood samplesDiagnostic test
As a substudy the maximum serum concentration of ropivacaine is analyzed. Blood samples are taken at 0, 15, 30, 45 and 60 minutes after block administration
Non-invasive blood pressure measurementDiagnostic test
Non-invasive blood pressure is measured prior to block administration and 30 minutes after block administration
| Study group | Role | What they receive |
|---|---|---|
| Active | Active comparator | Unilateral transmuscular quadratus lumborum block using 30 mL 0.75% ropivacaine Receives: Drug: Ropivacaine; Other: Quadriceps muscle strength; Other: Timed Up and Go; Other: Single-leg 6 meter timed hop test; Other: Temperature discrimination; Other: Pinprick test; Diagnostic Test: Blood samples; Diagnostic Test: Non-invasive blood pressure measurement |
| Placebo | Placebo comparator | Unilateral transmuscular quadratus lumborum block using 30 mL isotonic saline Receives: Other: Quadriceps muscle strength; Other: Timed Up and Go; Other: Single-leg 6 meter timed hop test; Other: Temperature discrimination; Other: Pinprick test; Diagnostic Test: Blood samples; Diagnostic Test: Non-invasive blood pressure measurement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maximum unilateral knee extension strength
The change in maximum, unilateral knee extension strength (newtonmeters (Nm)) comparing active and placebo TQL block, measured as the change from baseline to one hour after block administration.
Measured: One hour
Secondary outcomes (8)
Single-leg 6 meter timed hop test
Change in time performing the single-leg 6 meter timed hop test (Minutes, standardised protocol) comparing active and placebo TQL block, measured as the change from baseline to one hour after block administration.
Measured: One hour
Timed Up and Go test
Change in Timed Up and Go test (minutes, standardised protocol) from baseline to one hour after block administration
Measured: One hour
Dermatomal testing of thoracic and lumbar dermatomes
Dermatomal spread of the TQL block using standardised mechanical (pinprick) discrimination (number of dermatomes)
Measured: One hour
Dermatomal testing of thoracic and lumbar dermatomes
Dermatomal spread of the TQL block using standardised temperature (cold) discrimination (number of dermatomes).
Measured: One hour
Dermatomal testing of thoracic and lumbar dermatomes
Dermatomal spread of the TQL block using standardised temperature (warmth/heat) discrimination (number of dermatomes).
Measured: One hour
Non-invasive blood pressure (Mean arterial pressure)
Change in non-invasive blood mean arterial pressure from baseline to T30min (mmH
Measured: 30 minutes
Adverse events
Number of adverse events
Measured: At least 2 hours post block administration
Total ropivacaine serum concentration
Total concentration of ropivacaine at 0, 15, 30, 45 and 60 minutes following administration of the unilateral TQL block.
Measured: One hour
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Aug 2021
- Study start2 Oct 2021
- Primary completion28 Nov 2021
- Study completion28 Nov 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Neuromuscular BlockadeStudies of the same condition, open and under way.
- More trials run by Zealand University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Each participant serves as their own control i.e. each participant will receive both an active and placebo block TQL block. Left/right side are randomized.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zealand University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Katrine Tanggaard, MD, Principal investigator, Zealand University Hospital, Department of Anaesthesiology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05023343
- Sponsor's protocol ID
- SUH-TQL-QUADRICEPS
- Status last verified
- Dec 2021
- First submitted
- 17 Aug 2021
- Last updated
- 21 Dec 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Tanggaard K, Nielsen MV, Holm UHU, Hoffmann BM, Bernhoff C, Andersen CH, Thomassen SS, Hansen C, Dam M, Poulsen TD, Holm PM, Borglum J. No quadriceps muscle weakness following anterior quadratus lumborum block compared with placebo: a randomized, non-inferiority, blinded, volunteer trial. Reg Anesth Pain Med. 2025 Jul 4;50(7):568-574. doi: 10.1136/rapm-2024-105313.
PubMed 38754991
Study at a glance
From the registry record, last updated by the sponsor on 21 Dec 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does Administration of the Transmuscular Quadratus Lumborum Block Cause Quadriceps Muscle Weakness: A Randomised, Double-blinded Volunteer Study
- ClinicalTrials.gov ID
- NCT05023343
- Acronym / sponsor ID
- SUH-TQL-QUADRICEPS
- Conditions
- Neuromuscular Blockade
- Keywords
- Quadratus lumborum, Quadratus lumborum block, Ultrasound, Muscle weakness
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Zealand University HospitalUniversity, hospital or other
- Study start
- 2 Oct 2021 (actual)
- Primary completion
- 28 Nov 2021 (actual)
- Study completion
- 28 Nov 2021 (actual)
- First posted
- 26 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to examine whether the administration of the TQL block cause motor block of the lumbar plexus and thereby quadriceps muscle weakness. The investigators hypothesise that the administration of a unilateral TQL block does not cause quadriceps muscle weakness compared to a placebo block.
Detailed description
The ideal postoperative analgesic regimen following major abdominal and retroperitoneal laparoscopic surgery still lacks consensus and the discussion is ongoing. The epidural blockade has been the gold standard for postoperative pain management for major abdominal surgery for years, but with the conversion to minimal invasive surgery the procedure can rarely be justified.
The use of a multimodal analgesic regimen with opioids can cause severe side effects. These side effects can delay mobilisation after surgery, increase the risk of complications and worst of all be fatal.
The focus on an opioid sparing regimen, in the enhanced recovery setting, has been a significant motivator for the addition of ultrasound-guided nerve blocks to the perioperative progression.
At the Department of Anaesthesiology, Zealand University Hospital, the ultrasound-guided Transmuscular Quadratus Lumborum (TQL) block is part of the perioperative pain regimen for major laparoscopic abdominal and retroperitoneal surgeries, as well as for elective caesarean sections. Using the visual guidance of ultrasound, the injectate of local anaesthetic is administered in the fascial interspace between the quadratus lumborum muscle and the psoas major muscle posterior to the transversalis fascia.
This will anaesthetise the abdominal wall including both somatic and visceral nerves. No involvement of lumbar plexus i.e. the femoral nerve, obturator nerve or the lumbar part of the sympathetic trunk was observed. The lack of lumbar plexus involvement means no motor block of the lower extremities should be observed. Previous clinical studies reported no adverse events. However, the investigators did not specifically register lower limb weakness or hypotension, but on the other hand did not find any difference in ambulation or even faster ambulation compared to the placebo group.
A few case reports have reported complications related to the various quadratus lumborum blocks. Ueshima et al. reported that 90% (65/81 cases) experienced quadriceps muscle weakness following a TQL block. The incidence was 19% for posterior QL block and 1% for lateral QL block. Lower limb weakness was also reported by Wikner et al. following a bilateral lateral QL block. A case of continuous hypotension after administration of a lateral QL block has been described. One case of unilateral upper limb weakness and Horners Syndrome after a bilateral posterior QL block has also been reported. Urinary retention was reported following a continuous TQL-block. All side effects were temporary, no one reported permanent injuries. Complications have not been reported systematically.
At Zealand University Hospital, Roskilde, the investigators have administrated more than 1000 TQL blocks, and more than 300 patients have been included in various clinical trials. From clinical experience and cadaveric studies, the investigators find no evidence that the TQL block spread to the epidural space, and therefore does not cause sympathetic symptoms. Neither does the TQL block spread to the lumbar plexus, and therefore does not cause motor weakness of the lower extremities. However these notions have never been properly investigated in a controlled clinical setting, meaning that the investigators cannot entirely rule out the possibility of a spread to the lumbar plexus and thus ensuing quadriceps muscle weakness. This calls for a more in-depth investigation of this potential phenomenon.
Therefore, the aim of this study is to examine whether the administration of the TQL block cause motor block of the lumbar plexus and thereby quadriceps muscle weakness.
Prior to block administration all participants are tested using the same motor tests as after the block administration(baseline tests).
All participants will receive two TQL blocks. To keep participants and outcome assessors blinded the study drug for each side will be randomised i.e. active treatment on one side and placebo on the contralateral side.
The investigators hypothesise that the administration of a unilateral TQL block does not cause quadriceps muscle weakness compared to a placebo block.
Sub-study:
Fascial plane nerve blocks demand a great volume of local anaesthetic to achieve the right spread of local anaesthetic and thus a sufficient analgesia.
The correct concentration and volume of local anaesthetic is still debated. Studies measuring serum concentrations of local anaesthetic are rare due to time consumption and high costs. When administering a unilateral TQL block a volume of 30 ml local anaesthetic is used often equal to the maximum single-shot dose of ropivacaine; i.e. 225 milligrams. In previous studies and in the usual clinical setting the investigators have never experienced any signs of systemic toxicity, however the maximum serum concentration of local anaesthetic following TQL block administration has never been investigated. The maximum serum ropivacaine concentration following administration of a TQL block will therefore be investigated for all participants.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Each participant serves as their own control i.e. each participant will receive both an active and placebo block TQL block. Left/right side are randomized.
| Arm | Type | Receives |
|---|---|---|
| Active | Active comparator | Drug: Ropivacaine, Other: Quadriceps muscle strength, Other: Timed Up and Go, Other: Single-leg 6 meter timed hop test, Other: Temperature discrimination, Other: Pinprick test, Diagnostic Test: Blood samples, Diagnostic Test: Non-invasive blood pressure measurementUnilateral transmuscular quadratus lumborum block using 30 mL 0.75% ropivacaine |
| Placebo | Placebo comparator | Other: Quadriceps muscle strength, Other: Timed Up and Go, Other: Single-leg 6 meter timed hop test, Other: Temperature discrimination, Other: Pinprick test, Diagnostic Test: Blood samples, Diagnostic Test: Non-invasive blood pressure measurementUnilateral transmuscular quadratus lumborum block using 30 mL isotonic saline |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age ≥ 18 years
- American Associations of Anaesthesiologist (ASA) class 1-2
- Have received written and oral information and signed the consent form
- Weight > 56,5 kilograms (Chosen due to maximum single dose of ropivacaine i.e. 225 milligrams)
Key exclusion criteria (8 listed)
- Inability to speak and understand Danish
- Inability to cooperate
- Allergy to study drugs
- Daily intake of opioids
- Alcohol and/or drug overuse
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ropivacaine30 mL Ropivacaine 0,75% administered as a unilateral TQL block | Drug | Active |
| Quadriceps muscle strengthQuadriceps muscle strength is assessed using a hand-held dynamometer. Each participant is tested pre block administration and 60 minutes after | Other | Active, Placebo |
| Timed Up and GoTo test mobilisation the standardised Timed Up and Go test is used. Each participant is tested pre block administration and 60 minutes after | Other | Active, Placebo |
| Single-leg 6 meter timed hop testTo test muscle strength and power the single-leg 6 meter jump test is used. Each participant is tested pre block administration and 60 minutes after | Other | Active, Placebo |
| Temperature discriminationDermatomal evaluation of cold and warm discrimination of the thoracic and lumbar dermatomes Approximately 60 minutes after block administration | Other | Active, Placebo |
| Pinprick testDermatomal evaluation of pinprick/sharp sensation of the thoracic and lumbar dermatomes. Approximately 60 minutes after block administration | Other | Active, Placebo |
| Blood samplesAs a substudy the maximum serum concentration of ropivacaine is analyzed. Blood samples are taken at 0, 15, 30, 45 and 60 minutes after block administration | Diagnostic test | Active, Placebo |
| Non-invasive blood pressure measurementNon-invasive blood pressure is measured prior to block administration and 30 minutes after block administration | Diagnostic test | Active, Placebo |
Primary outcome
Maximum unilateral knee extension strength
Time frame: One hour
The change in maximum, unilateral knee extension strength (newtonmeters (Nm)) comparing active and placebo TQL block, measured as the change from baseline to one hour after block administration.
8 secondary outcomes
Single-leg 6 meter timed hop test
Time frame: One hour
Timed Up and Go test
Time frame: One hour
Dermatomal testing of thoracic and lumbar dermatomes
Time frame: One hour
Dermatomal testing of thoracic and lumbar dermatomes
Time frame: One hour
Dermatomal testing of thoracic and lumbar dermatomes
Time frame: One hour
Non-invasive blood pressure (Mean arterial pressure)
Time frame: 30 minutes
Adverse events
Time frame: At least 2 hours post block administration
Total ropivacaine serum concentration
Time frame: One hour
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Dec 2021.
- Derived from this study: PubMed 38754991Tanggaard K, Nielsen MV, Holm UHU, Hoffmann BM, Bernhoff C, Andersen CH, Thomassen SS, Hansen C, Dam M, Poulsen TD, Holm PM, Borglum J. No quadriceps muscle weakness following anterior quadratus lumborum block compared with placebo: a randomized, non-inferiority, blinded, volunteer trial. Reg Anesth Pain Med. 2025 Jul 4;50(7):568-574. doi: 10.1136/rapm-2024-105313.
- Individual participant dataSharing planned: No
Related trials for Neuromuscular Blockade
Active, not recruiting
Efficacy of Laparoscopic-Assisted TAP Block in Laparoscopic Appendectomy
Appendectomy, Laparoscopic, Blockades Neuromuscular
Not yet recruitingObservational study
Diaphragm Ultrasound and Neuromuscular Monitoring for Predicting Early Respiratory Events After Extubation
Residual Neuromuscular Blockade, Diaphragm Dysfunction
Recruiting
Inspiratory Muscle Training and Diaphragmatic Breathing in GAD
Generalized Anxiety Disorder (GAD)
Not yet recruiting
Comparative Effects Of Exercises Targeting Upper Trapezius In Patients With Non Specific Neck Pain
Non Specific Neck Pain
RecruitingObservational study
The Association Between Residual Neuromuscular Block Risk Prediction Score and the Train-of-Four Ratio
Muscle Relaxants
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Katrine Tanggaard, MD principal investigator
Zealand University Hospital, Department of Anaesthesiology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Ropivacaine, Quadriceps muscle strength and Timed Up and Go in people with Neuromuscular Blockade, run by Zealand University Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maximum unilateral knee extension strength (time frame: One hour). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05023343, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Dec 2021.